var data={"title":"Sodium phenylacetate and sodium benzoate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sodium phenylacetate and sodium benzoate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6969?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sodium-phenylacetate-and-sodium-benzoate-drug-information\" class=\"drug drug_general\">see &quot;Sodium phenylacetate and sodium benzoate: Drug information&quot;</a> and <a href=\"topic.htm?path=sodium-phenylacetate-and-sodium-benzoate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sodium phenylacetate and sodium benzoate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221922\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ammonul</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062250\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Ammonium Detoxicant</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Hyperammonemia Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Urea Cycle Disorder (UCD) Treatment Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12675757\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Administer as a loading dose over 90 to 120 minutes, followed by an equivalent dose as a maintenance infusion over 24 hours. Initiate therapy as soon as the diagnosis of hyperammonemia is made; therapy should continue until ammonia levels are in normal range or patient can tolerate oral nutrition and medications. Antiemetics may be administered during infusion to aid control of infusion-associated nausea and vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperammonemia, acute (urea cycle disorders [UCD]): Note: </b>Administer concomitantly with arginine; arginine dose varies based on type of UCD. Ammonul: IV: Loading dose: 2.5 mL/kg (provides sodium phenylacetate 250 mg/kg and sodium benzoate 250 mg/kg) followed by maintenance infusion of 2.5 mL/kg/24 hours (provides sodium phenylacetate 250 mg/kg and sodium benzoate 250 mg/kg per 24 hours)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062243\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=sodium-phenylacetate-and-sodium-benzoate-drug-information\" class=\"drug drug_general\">see &quot;Sodium phenylacetate and sodium benzoate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: </b>Administer as a loading dose over 90 to 120 minutes, followed by an equivalent dose as a maintenance infusion over 24 hours. Dosage is based on weight for infants and young children and body surface area for older children and adolescents. Initiate therapy as soon as the diagnosis of hyperammonemia is made; therapy should continue until ammonia levels are in normal range or patient can tolerate oral nutrition and medications. Antiemetics may be administered during infusion to aid control of infusion-associated nausea and vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperammonemia, acute (urea cycle disorders [UCD]): Note: </b>Administer concomitantly with arginine; arginine dose varies based on type of UCD. Ammonul: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &le;20 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose: 2.5 mL/kg (provides sodium phenylacetate 250 mg/kg and sodium benzoate 250 mg/kg) followed by maintenance infusion of 2.5 mL/kg/24 hours (provides sodium phenylacetate 250 mg/kg and sodium benzoate 250 mg/kg per 24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents &gt;20 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose: 55 mL/<b>m<sup>2</sup></b> (provides sodium phenylacetate 5.5 g/m<sup>2</sup> and sodium benzoate 5.5 g/m<sup>2</sup>) followed by maintenance infusion of 55 mL/<b>m<sup>2</sup></b>/24 hours (provides sodium phenylacetate 5.5 g/m<sup>2</sup> and sodium benzoate 5.5 g/m<sup>2</sup> per 24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in renal impairment:</b> Use with caution; monitor closely</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dialysis: Ammonia clearance is &sim;10 times greater with hemodialysis than by peritoneal dialysis or hemofiltration. Exchange transfusion is ineffective.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in hepatic impairment:</b> Use with caution</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221905\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution [concentrate]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ammonul: Sodium phenylacetate 100 mg and sodium benzoate 100 mg per 1 mL (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: Sodium phenylacetate 100 mg and sodium benzoate 100 mg per 1 mL (50 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221891\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062254\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Must dilute prior to administration; may administer in combination with arginine. Must be administered via central line; administration via peripheral line may cause burns. Infuse loading dose over 90 to 120 minutes; maintenance dose is a continuous infusion infused over 24 hours. Antiemetics may be needed to decrease nausea during infusion. May be an irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation (may cause necrosis). If extravasation is suspected discontinue infusion and resume at a different infusion site (if necessary).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221918\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Following dilution, solution for infusion may be stored at room temperature for up to 24 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062253\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Adjunct to treatment of acute hyperammonemia and encephalopathy in patients with urea cycle disorders (FDA approved in all ages)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221938\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia, cardiac failure, cardiogenic shock, cardiomyopathy, chest pain, edema, flushing, hepatic artery stenosis, hypertension, hypotension (more common in neonates), low cardiac output, myocardial rupture (atria), pericardial effusion, septic shock, subdural hematoma, thrombosis, venous thrombosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Absent reflexes, acute psychosis, aggressive behavior, agitation, ataxia, brain disease, cerebral atrophy, cerebral edema, cerebral hemorrhage, cerebral herniation, cerebral infarction, clonus, coma, confusion, decreased mental acuity, hallucination, impaired consciousness, increased intracranial pressure, paralysis (nerve), seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, maculopapular rash, pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Acidosis, alkalosis, dehydration, fluid retention, hyperammonemia, hyperglycemia, hyperkalemia, hypernatremia, hypervolemia, hypocalcemia, hypokalemia, metabolic acidosis, respiratory acidosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distention, cholestasis, diarrhea (more common in infants), gastrointestinal hemorrhage, nausea (more common in infants), vomiting (more common in infants)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Anuria, urinary retention, urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Altered serum glucose, anemia, blood coagulation disorder, disseminated intravascular coagulation (DIC), hemangioma, hemorrhage, increased serum pH, pancytopenia, pulmonary hemorrhage, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatic failure, hepatotoxicity, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection, sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction (includes extravasation, hemorrhage at injection site, injection site blister formation)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Tetany, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blindness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Acute respiratory distress, aspiration pneumonia, dyspnea, hypercapnia, hyperventilation, Kussmaul&rsquo;s respiration, pneumothorax, pulmonary edema, respiratory alkalosis, respiratory distress, respiratory insufficiency, tachypnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever, multi-organ failure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221911\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221895\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute hyperammonemia: Uncontrolled hyperammonemia can result in brain death. Immediate use of all additional therapies to decrease ammonia levels is essential including hemodialysis, caloric supplementation, and dietary protein restriction. Nonprotein calories should be supplied primarily as glucose (8 to 10 mg/kg/minute) with the addition of IV fat emulsion; attempts should be made to maintain a caloric intake of &gt;80 cal/kg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Infuse via central line ONLY; peripheral administration may cause burning. May be an irritant with vesicant-like properties; avoid extravasation. If extravasation is suspected discontinue infusion and resume at a different infusion site (if necessary).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid overload: Use with caution, if at all, in patients at risk for fluid overload (eg, heart failure, severe renal impairment) or sodium retention edema; contains a significant amount of sodium. Discontinue use if patient experiences clinically significant fluid overload.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal effects: Nausea and vomiting may occur; premedication with antiemetics may be administered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypokalemia: May occur; monitor plasma potassium and initiate appropriate treatment as necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Metabolic acidosis/hyperventilation: Use may cause hyperventilation and metabolic acidosis; phenylacetate and benzoate are structurally similar to salicylate, therefore, adverse effects typically associated with salicylate overdose may occur with sodium phenylacetate/sodium benzoate use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity: Phenylacetate may result in neurotoxicity (fatigue, lightheadedness, somnolence); symptoms were observed upon initiation of treatment and were reversible with discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; metabolism of sodium phenylacetate/sodium benzoate may be impaired.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; excretion of drug metabolites (phenylacetylglutamine and hippurate) and ammonia may be reduced since primarily excreted by the kidneys; use may also predispose to fluid overload.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neonates: Hyperammonemic coma, regardless of the cause, should be treated aggressively until a specific diagnosis is made. Hemodialysis should be initiated immediately in all neonates and may be repeated until plasma ammonia level is stable at normal or near normal levels; a blood flow rate of 150 mL/minute/m<sup>2</sup> should be targeted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sodium benzoate: Contains sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Initiate therapy as soon as hyperammonemia is diagnosed. Must be diluted prior to administration. Administer through a central line; peripheral administration may result in burning. Repeat loading doses should not be administered (may result in prolonged phenylacetate plasma levels). Arginine supplementation is an essential part of therapy for patients with carbamyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC), argininosuccinate synthetase (ASS), or argininosuccinate lyase (ASL) deficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced personnel: Patients should be managed by medical personnel experienced in the treatment of metabolic disorders.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25956040\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Enhanced potassium excretion may occur with treatment of hyperammonemia, monitor serum potassium concentration closely. Repeat loading doses of drug are not indicated due to prolonged plasma levels noted in pharmacokinetic studies. Maintain caloric intake of &gt;80 cal/kg/day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300065\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6223020\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12951&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Sodium Phenylacetate. Specifically, probenecid may inhibit the renal transport of the phenylacetylglutamine metabolite of sodium phenylacetate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Sodium Benzoate. Specifically, probenecid may inhibit the renal transport of the hippuric acid metabolite of sodium benzoate.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221900\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221914\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted with this combination.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062249\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Plasma ammonia, plasma amino acid (quantitative) and glutamine concentrations, blood glucose, serum electrolytes, hepatic and renal function tests, blood gases, neurologic status, physical signs/symptoms of hyperammonemia (ie, lethargy, ataxia, confusion, vomiting, seizures, and memory impairment); infusion site</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062252\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Long-term target levels (may not be appropriate for every patient) (Berry 2001):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Plasma ammonia: &lt;40 &mu;mol/L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Plasma glutamine: &lt;1000 &mu;mol/L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Normal plasma levels of alanine, glycine, lysine, arginine (except in arginase deficiency); no subnormal concentrations of essential amino acids (eg, leucine, isoleucine, valine)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221894\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Sodium phenylacetate and sodium benzoate provide alternate pathways for the removal of ammonia through the formation of their metabolites. One mole of sodium phenylacetate removes two moles of nitrogen; one mole of sodium benzoate removes one mole of nitrogen.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221910\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic and renal; sodium phenylacetate conjugates with glutamine, forming the active metabolite, phenylacetylglutamine (PAG); sodium benzoate combines with glycine to form the active metabolite hippuric acid (HIP) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323874\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ammonul Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-10% (50 mL): $54,792.83</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Sod Benz-Sod Phenylacet Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-10% (50 mL): $43,800.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phenylacetate-and-sodium-benzoate-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ammonul (sodium phenylacetate and sodium benzoate) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Batshaw ML, MacArthur RB, and Tuchman M, &ldquo;Alternative Pathway Therapy for Urea Cycle Disorders: Twenty Years Later,&rdquo; <i>J Pediatr</i>, 2001, 138(1 Suppl):46-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phenylacetate-and-sodium-benzoate-pediatric-drug-information/abstract-text/11148549 /pubmed\" target=\"_blank\" id=\"11148549 \">11148549 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berry GT and Steiner RD, &ldquo;Long-Term Management of Patients With Urea Cycle Disorders,&rdquo; <i>J Pediatr</i>, 2001, 138(1 Suppl):56-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phenylacetate-and-sodium-benzoate-pediatric-drug-information/abstract-text/11148550/pubmed\" target=\"_blank\" id=\"11148550\">11148550</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brusilow SW, Danney M, Waber LJ, et al, &ldquo;Treatment of Episodic Hyperammonemia in Children With Inborn Errors of Urea Synthesis,&rdquo; <i>N Engl J Med</i>, 1984, 310(25):1630-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phenylacetate-and-sodium-benzoate-pediatric-drug-information/abstract-text/6427608 /pubmed\" target=\"_blank\" id=\"6427608 \">6427608 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol--United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phenylacetate-and-sodium-benzoate-pediatric-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gutteridge C and Kuhn RJ, &ldquo;Compatibility of 10% Sodium Benzoate Plus 10% Sodium Phenylacetate With Various Flavored Vehicles,&rdquo; <i>Am J Hosp Pharm</i>, 1994, 51(19):2508, 2510.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phenylacetate-and-sodium-benzoate-pediatric-drug-information/abstract-text/7847413/pubmed\" target=\"_blank\" id=\"7847413\">7847413</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Summar M, Tuchman M. Proceedings of a consensus conference for the management of patients with urea cycle disorders. <i>J Pediatr</i>. 2001;138(1 Suppl):S6-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phenylacetate-and-sodium-benzoate-pediatric-drug-information/abstract-text/11148544/pubmed\" target=\"_blank\" id=\"11148544\">11148544</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Urea Cycle Disorders Conference group. Consensus statement from a conference for the management of patients with urea cycle disorders. <i>J Pediatr</i>. 2001;138(1 Suppl):S1-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phenylacetate-and-sodium-benzoate-pediatric-drug-information/abstract-text/11148543/pubmed\" target=\"_blank\" id=\"11148543\">11148543</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12951 Version 60.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F221922\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1062250\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F12675757\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1062243\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F221905\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F221891\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1062254\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F221918\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1062253\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F221938\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F221911\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F221895\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25956040\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300065\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6223020\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F221900\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F221914\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1062249\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1062252\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F221894\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F221910\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323874\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12951|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sodium-phenylacetate-and-sodium-benzoate-drug-information\" class=\"drug drug_general\">Sodium phenylacetate and sodium benzoate: Drug information</a></li><li><a href=\"topic.htm?path=sodium-phenylacetate-and-sodium-benzoate-patient-drug-information\" class=\"drug drug_patient\">Sodium phenylacetate and sodium benzoate: Patient drug information</a></li></ul></div></div>","javascript":null}